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ABSTRACT
With advancements in CRISPR-cas9 broadening the potential paths for
clinical usage of genetic editing, conversations about genetic editing have grown to
outside simply scientific communities and into mainstream conversations. This study
focuses specifically on Christian discourse of genetic editing and locates four major
tensions for many Christians when they think about genetic editing: beginning of life,
Creator-human relationship, imago Dei, and stewardship. With these major concerns
in mind, I identify epigenetics, somatic cell genetic editing, and in vivo genetic editing
research as important research paths to pursue as they can potentially produce
techniques that more Christian individuals would feel comfortable using. I pursue
one of these paths and conclude with an experimental proposal for an analysis of in
vivo and in vitro CIRSPR-Cas9 efficiency in regards to on- and off-target rates.
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INTRODUCTION
Not only is genetic editing and its rapid advancements a topic within the
scientific community, it has been incorporated into mainstream conversations.
Specifically, the discovery of and recent enhancements of the genetic editing
technique, CRISPR-cas9, has made genetic editing more feasible and efficient. This
method looks for a target sequence of DNA, using a complementary single-stranded
guide RNA. The complex then creates a double stranded break at the target location
and enables DNA repair off of an introduced donor DNA to replace the target
sequence with a preferred mutation. This technique is scientifically exciting because
of its versatility and facile targeting of a multitude of sequences. This advancement
has shown that genetic editing could feasibly be utilized as a clinical treatment. This
future possibility has sparked numerous discussion on whether or not we should be
genetically editing in the first place.
Individuals base their opinions on a variety of sources, but one major source
that informs opinions on this moral decision is religion. Genetic editing can only be
helpful if it is acceptable and therefore applicable to possible users. PEW conducted
a study on the potential usage of gene-editing amongst different categories of the
American public (Street, NW, Washington, & Inquiries, 2013). An analysis of this
data has shown that highly religious Americans are “much more likely than those
who are less religious to say they would not want to use gene-editing technology in
their families”(Funk, Kennedy, & Sciupac, 2016). This is important as it highlights the
patterns and trends within public attitudes about gene-editing and confirms the
notion that current genetic technologies are not accessible to religious communities.
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Since religion can be a major contributor to a person’s evaluation of genetic editing,
if clinical benefits and care are to be extended, there is a need to develop
techniques with which individuals can potentially agree. In addition, scholars have
discussed the need for more conversation about genetics within faith communities
as an attempt to answer any clarifying questions and produce a more transparent
relationship between the two communities (Joseph, 2016). This project builds upon
this plea for more well-informed conversations about genetics within religious
communities, by going further and working on how the scientific community can also
benefit by information about religious communities and not just the other way
around.
This thesis will look specifically at the more conservative Christian discourse
on genetic editing and possible paths for genetic editing research that would be
more accepted by Christian communities. The general understanding of the
Christian stance on genetic editing is that the Christian tradition simply does not
approve it. However, this generalization fails to account for the complexity of
Christian concerns and the opportunity for potential acceptance within the tradition.
In order to deduce potential acceptable paths of genetic editing, I identify four
“tension zones” (beginning of life, Creator-human relationship, imago Dei, and
stewardship) within the Christian discourse. These tension zones are areas within
the discourse that are both important concerns within the Christian community, but
also house contradictions and potential avenues for acceptance of genetic editing. I
argue within those four tension zones, the Christian stewardship concern of harm
and the need for the conjugal act in the creation of new life are specific areas that
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should be taken into consideration in order to find Christian-acceptable genetic
editing research paths: epigenetics, somatic gene therapy, and in vivo genetic
editing. In culmination, I propose an analysis of in vivo and in vitro CRISPR-Cas9
efficiency in regards to on- and off-target rates; on-target rates measure the amount
of correct mutations of the intended gene sites, while off-target rates measure the
amount of mutations of unintended gene sites. A reduction of off-target effects could
potentially make a genetic editing method more clinically viable, as the potential
“harm” or risk associated with the technique would be lower.
This is a dual religious studies and biology thesis and incorporates both fields
of study to form a comprehensive analysis of Christian discourse of genetic editing
and its relevancy to the scientific study. A greater goal of this thesis is to motivate
the scientific field to consider the concerns of the potential users of their techniques
and thus, produce more acceptable and comfortable clinical methods and therapies.
This then has the potential to greatly increase the accessibility of clinical genetic
editing, in terms of whether or not individuals will feel comfortable with their genetic
editing techniques and consider it a viable option. I hope to show the benefits of this
interdisciplinary approach and spark more discussions between the scientific and
religious communities, that normally tend to be separate.

7

CHAPTER ONE.
CHRISTIAN STANCES ON GENETIC EDITING:
RESISTANCE AND OPENNESS
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Introduction
Sitting in the waiting rooms of obstetrics and gynecology medical facilities are
countless individuals who are not only thinking about Pap smears, STI testing,
fertility, pregnancy and birth control, but today have to think about questions
regarding genetic testing and editing. With the rapid development of genetic
technologies such as CRISPR-Cas9 genome editing, the genetic editing of embryos
is more realistic than ever before. These questions about genetic editing exist not
only at OBGYN offices, but also in segments of life that pertain to one’s own life
instead of future children. Genetic technology research ranges from the genetic
editing of eggs and sperm to discovering the intricacies of cancer through genetic
events (Sánchez-Rivera et al., 2014, p. 428).
The common misunderstanding of the Christian stance on genetic
engineering is that the tradition simply does not agree with it; however, this quick
assumption ignores the distinct complexities within Christian dialogue surrounding
genetics and the possibilities for developing more acceptable forms of genetic
engineering. Although there are similar Christian concepts used in arguments for
and against genetic editing, the way they are used can contradict each other. These
contradictions present within the discourse highlight tension zones within the
Christian tradition which contain particularly complex or contradictory
understandings. These zones can be utilized by scholars when developing novel
avenues of future genetic research, as there are multiple Christian interpretations to
possibly align with.
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I argue that the Christian discourse of genetic editing is rooted in four major
concepts (the beginning of life, Creator-human relationship, imago Dei, and
stewardship) and that although these concepts inform individual arguments, the
defining factor between support and rejection is the perception of genetic editing in
relation to harm; support of genetic editing is grounded in the categorization of
genetic editing as a reduction of harm, while rejection is due to the categorization of
it as inflicting harm. Two major concepts utilized by Christian arguments against
genetic editing are the beginning of life and the Creator-human relationship.
However amongst these, each argument has a uniquely nuanced understanding of
the Christian concept. While still being informed by the Christian understanding of
the beginning of life and Creator-human relationship, some arguments that support
and reject genetic editing incorporate the concepts of imago Dei and stewardship.
Although these two categories have arguments against genetic editing, here I also
locate Christian support for genetic editing, which is a product of understanding
genetic editing as reducing harm in some way rather than inflicting harm
Because of the notion that the Christianity and genetic editing occupy
completely separate spaces, there is a significant lack of communication between
religious and scientific communities. This has led to misinformed preconceptions
regarding both the mechanisms and opinions of genetic editing. Thus, genetic
editing research has evolved in heavy isolation from religious communities,
producing genetic technologies that are scientifically intuitive but not as widely
accepted by the religious public. Genetic editing research is only beneficial if it can
actually help people, which can only happen if the techniques are accessible to a
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broad patient spectrum. This chapter’s work in identifying individual Christian
arguments about genetic editing, locating the tension zones, and highlighting the
defining harm factor between rejection and support of genetic editing, is important as
it starts the journey towards producing genetic technologies that can possibly be
more accepted by a religious public.
Thus in this chapter, I present individual Christian arguments for and against
genetic editing. As mentioned, arguments about genetic editing make use of four
major Christian tension zones: beginning of life, Creator-human relationship, imago
Dei, and stewardship. The use of these concepts creates tension whereby the
arguments utilize a general concept in contradictory or different ways. In what
follows, the individual arguments are presented under the tension zone in which they
fall. Their rejection or support of genetic editing is explained based on whether
genetic editing is categorized as reducing or inflicting harm.

Beginning of Life
Within the medical field there is a very present debate on what stage life
begins: Is a zygote a bundle of cells or a unique life? Can a fetus or embryo be alive
if it is not self-sustaining? Although this is a debated topic amongst medical
professions, the conservative Christian understanding of the beginning of life is
rather concrete: at the moment of conception. In its ethics statement, the Christian
Medical & Dental Association writes that “the Bible states that human life begins at
the absolute beginning or inception using the term ‘conception’”; and in order to
clarify any confusion about the moment of conception, situates it as “the point of
fertilization”. (Christian Medical & Dental Associations, 2006, p. 14). This
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understanding is also at the root of the Catholic Church’s teachings on the care of
human life, instructing a “protection of life in all its stages, from the first moment of
conception until natural death” (Benagiano & Mori, 2007, p. 162). The Christian
understanding of the beginning of life is specifically relevant to the topic of genetic
editing, as it informs the majority of Christian arguments rejecting and supporting
genetic editing. This section will analyze how two arguments utilize the Christian
beginning of life as the primary reasoning for the rejection of genetic editing.
Within the Christian discourse of genetic editing, arguments against the use
of embryo-derived stem cells within genetics research heavily draw upon the
understanding that life begins at conception. Stem cells are a unique type of cell that
can “reproduce themselves, and can also generate daughter cells that become
differentiated cells” (Slack, 2012, p. 3). These differentiated cells then come to form
specified units of cells that develop into different parts of the body. Stem cells are
particularly useful within genetics as they provide a “self-renewing population of cells
and thus may reduce or eliminate the need for repeated administrations of the gene
therapy” (U.S. Department of Health & Human Services, 2001). If a gene is modified
within a stem cell, the subsequent cells and body units that are derived from that
initial cell will also carry that modification; this mechanism is the basis of the
administrative and research benefit of stem cells in genetics. There are two major
categories of stem cells: adult and embryonic. Although stem cells can be derived
from both sources, there are two major benefits of using embryonic stem cells: they
are easier to extract and culture; and they are able to differentiate into a more a
variety of cell types. One major Christian argument against stem cell usage within
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research is that it would entail the “death” of a fetus or embryo; this argument fails to
incorporate adult-stem cells that are not embryo-derived. Rooted in the Christian
notion of the beginning of life, the U.S. Conference of Catholic Bishops states that
“every living member of the human species, including the human embryo, must be
treated with the respect due to a human person” (U.S. Conference of Catholic
Bishops, 2004). Under this model, any use of stem cells “wraps the user in a state of
complicit guilt, because the only way the stem cells could be used is at the earlier
expense of an embryo or fetus” (Modell, 2007, p. 173). This rejection of genetic
editing techniques due to its usage of stem cells is grounded in the specific Christian
understanding of the beginning of life being at the moment of conception, which then
categorizes an embryo as living and embryo-derived stem cell techniques as “killing”
lives.
While still utilizing reasoning rooted in the Christian beliefs about the
beginning of life, some arguments against genetic technologies include the conjugal
act as a necessary precursor for the creation of life. According to the Vatican, the
conjugal act is established by God and serves both as unitive for the married couple
and procreative (Pope Benedict XVI, 2006). In a letter addressing scientific
advancements, the Vatican International Theological Commissions writes that “if a
technique is used that does not assist the conjugal act in attaining its goal, but
replaces it, and the conception is then effected through the intervention of a third
party, then the child does not originate from the conjugal act which is the authentic
expression of the mutual gift of the parents” (Vatican International Theological
Commission, 2004). Here, the Vatican is addressing a specific scientific
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advancement used within genetics, in vitro fertilization (IVF). IVF is clinically used as
a reproductive technology that fertilizes a mature egg with sperm outside of the body
and in a lab. This now fertilized egg is then implanted in the female’s uterus in hopes
of maturing into an embryo (Sher, Davis, & Stoess, 2005, p. 64). This technology is
useful for genetic techniques as it can be used in order to easily modify the genes of
the, sperm, egg, and fertilized egg. IVF is currently not compatible with Vatican’s
necessity of the conjugal act in the beginning of new life, as it circumvents any
necessary physical sexual intercourse between the married couple. Thus, the
Vatican frames one of its arguments against genetic editing in its usage of IVF and
the creation of life without the God ordained conjugal act.
Within the Christian discussion of genetic editing, many religiously based
arguments draw from the Christian understanding of the beginning of life at the
moment of conception and induced by conjugal act; although these arguments are
building upon the same general concept, they are calling into action different
components of the beginning of life. This complexity in Christian reasoning allows for
those within the tradition to align or disagree with any one of the many varieties
within the discourse, while still overall holding a Christian stance on genetic editing.
This complexity within elements of the Christian beginning of life still lead to a
rejection of genetic editing, however. An understanding of these objections can be
important for future genetics researchers to keep in mind as they research new
genetic technologies and mechanisms.
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Creator and Human Relationship
The perception of what being a human entails can vary from community to
community. The Christian understanding of the elements of being a human is deeply
attached to the understanding of God. Within the Christian tradition and specifically
in the two creation story accounts of the Bible, God is defined as the Creator and the
rest is God’s creation. In these accounts, the God’s creations are never said to
independently create any other creatures. This characteristic Creator-human
relationship has a stark divide between the two and allows little to none movement
between the two roles. This firm relationship is relevant to this study of genetic
editing debates, as it can serve as a basis to guide individuals’ judgements of
genetic editing based on whether it is compatible with the human’s role or if it tries to
“play” Creator. In order to understand how the Christian Creator-human relationship
is utilized within the discourse, two major arguments will be analyzed within this
subsection: Agneta Sutton’s and Mathias Beck’s rejections of genetic editing.
One major argument that utilizes the Christian understanding of the Creatorhuman relationship is Sutton’s rejection of the use of genetic germline editing.
Germline cells, such as eggs or sperm, are those cells whose genes are heritable
and transmitted to an offspring. On the other hand, somatic cells are not heritable
cells and can be found in the other various other parts of the body. Thus, germline
genetic editing affects the future progeny. In her argument, Sutton addresses
parents as her audience and urges them to reject germline genetic editing, as it both
oversteps the Christian human role and fails to respect children as a gift from God.
Sutton’s understanding of the Christian hierarchical relationship is that humans do
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not have the right or power to alter themselves and their lives; Sutton writes that
“there are both physical and moral limits to our powers. As Christians we recognize
that our lives are in God’s hands and that ultimately we cannot save ourselves or
others” (Sutton, 2012, p.153). Sutton expands on this understanding of God’s power
and the human lack of power when writing,
Accepting children as gifts means not making their welcome depend on
whether they satisfy standards set by us of health, ability, or beauty. At issue
are human attitudes and aspirations that undermine the welcome of the child
as a gift and deny it the respect it deserves as another person whose life
comes to us as a gift from God. (Sutton, 2012, p.149)
For Sutton, children are gifts from God and creatures whose components are all God
ordained and thus off-limits to human controlled modification. Any modification of
them is considered a failure to unconditionally welcome God’s gift and ultimately a
form of harming this life. Using this understanding, any form of germline genetic
editing is seen as a clear disrespecting and harming of God’s creation, God’s gift to
humans. In this argument Sutton is specifically addressing parents and therefore
only addresses germline genetic editing as it is extremely applicable to reproductive
decisions. However, based on the understanding of the Creator-human roles used in
this argument, God as the Creator and humans as gifts from God, it seems that
Sutton would also oppose all genetic editing because any modification would be in
fact modifying God’s gift. Thus, Sutton utilizes an understanding of the distinct roles
of God and humans and an understanding of modification as harm to support a
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rejection of genetic editing should. For Sutton, genetic editing is both an attempt of
humans overstepping the Creator-human divide and a mistreatment of God’s gift.
Looking at the creator-human relationship from another angle, Matthias Beck
also positions the God-human relationship at the forefront of the rejection of genetic
editing. Beck works within an epigenetic framework. Epigenetics is a relatively new
sub-field of genetics that explores how environmental conditions can affect and
change “gene activity without changing the DNA sequence” and can lead to
“modifications that can be transmitted to daughter cells”(Weinhold, 2006, p. A163).
These environmental conditions are commonly referred to as drivers or agents.
Beck’s explains his understanding of epigenetics when he writes,
Bodily relation-events reach down to genetic linkages. Genes are not merely
present, in their damaged or healthy form, but they interact, and they can be
switched on or off. Only switched-on genes are effective. The mechanisms for
such switching are only partially known so far. But it seems that the brain, and
thus a person’s thinking and feeling, is involved in them. (Beck, 2007, p. 79)
Although there are scientific studies that link traumatic emotional events to
epigenetic modifications, Beck’s description misrepresents this modification as
something that a person can easily turn off/on just by thinking. Current findings in
epigenetics identify possible drivers as: “heavy metals, pesticides, diesel exhaust,
tobacco smoke, polycyclic aromatic hydrocarbons, hormones, radioactivity, viruses,
bacteria, and basic nutrients”; these drivers and their epigenetic effects have been
linked to a variety of illness and health indicators such as “cancers of almost all
types, cognitive dysfunction, and respiratory, cardiovascular, reproductive,
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autoimmune, and neurobehavioral illnesses” (Weinhold, 2006, p. A160). Although
this is the scientific explanation of epigenetics, Beck describes epigenetic
mechanisms when stating,
Many diseases have genetic backgrounds. Defective genes, however, do not
necessarily lead to subsequent illness. Genes have to be switched on or off.
Only activated genes trigger pathological change. The human brain and all of
man’s thinking and feeling are intimately connected with such activations. We
may thus conclude that both inner life and religious outlook on life are
relevant to the origin and development of diseases. (Beck, 2007, p. 67)
Beck’s understanding of the Creator-human relationship fuels his claim that
epigenetic drivers are in direct derivatives of an individual’s relationship with God
and that this relationship is what dictates whether God “switches” the genes on or
off. Therefore, the human modification of genes would not be effective in actually
reaching a desired outcome, because God has the “real” power over genetic
activation. Under this model, genetic editing as a way of medical therapy for
diseases is not targeting the true source and therefore not reducing any harm to life.
Instead, Beck is arguing for individuals to spend their time investing in their
relationships with God, as that is the initial cause; God has the power to then turn on
or off the selected genes.
The Christian understanding of the Creator-human relationship utilized in both
Sutton’s and Beck’s arguments describe a firm hierarchal divided relationship
between humans and God; God has the control over the creation and the creation
do not have control to modify themselves. Sutton adds a complexity to this
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understanding by claiming that humans are not only creations but also gifts from
God that are warranted an unconditional welcome into the world. This then positions
genetic editing as both a breach of the Creator-human divide but also as a
mistreatment and harm of the lives of God’s creation. Beck includes an epigenetic
element to the Creator-human relationship that explains epigenetic events as direct
products of a stressed Creator-human relationship. Genetic editing is then
understood as an ineffective approach to reducing any harm caused by genetic
conditions; instead, Beck advocates for individuals to fix their relationships with God
which will then allow for the possibility of God turning on or off particular genes.
Even though both arguments each employ elements of the Creator-human
relationship as evidence for the rejection of genetic editing, there is diversity in what
sub-elements regarding the reduction or accretion of harm are utilized.

Imago Dei
In the Christian tradition not only do the concepts of the beginning of life and
the Creator-human relationship guide individuals’ judgements of genetic editing, but
also the Christian concept of imago Dei (“image of God”) plays a major role in the
Christian rejection and support of genetic editing. A common biblical verse that
informs the community of imago Dei is Genesis 1:27, “So God created man in His
own image, in the image of God He created him; male and female He created them”
(New International Version). Imago Dei informs the Christian understanding of the
nature of human creation and identity as direct expressions of God. This concept
manifests itself in Christian life as it expresses a “foundational relationship between
God and man, with implications for properly appreciating basic human goods and
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human flourishing, which in turn have repercussions for medical decision-making”
(Cherry, 2017, p.219). Specifically, imago Dei is used within the Christian discourse
of genetic editing in three major ways: imago Dei as a necessary understanding that
prevents development of immoral reproductive ethos; imago Dei as the basis of the
categorization of genetic editing as a mistreatment of a gift that is made in the image
of God; imago Dei as the reasoning behind a support of genetic editing as a means
to help individuals express their true identity.
When addressing a wide range of reproductive medicine that includes
prenatal genetic testing, in vitro fertilization, and abortion, some arguments rely on
imago Dei as a necessity that prevents individuals from developing a misinformed
stance on reproductive issues. Associate Senior Editor of Christian Bioethics, Mark
Cherry expresses the importance of imago Dei, when writing “Reference to the
Imago Dei expresses a foundational relationship between God and man, with
implications for properly appreciating basic human goods and human flourishing,
which in turn have repercussions for appropriate medical decision-making” (Cherry,
2017, p.219). He later claims that when the Christian or general body forgets that all
humans are made in the image of God, an ethical reproductive ethos forms that
“normalizes not only contraception to control when to have children and medical
selection of embryos for desirable traits through assisted reproductive technology,
but also prenatal diagnosis and selective killing in utero of children with a likelihood
of disabilities or undesirable genetic characteristics” (Cherry, 2017, p.224). This
argument utilizes not only imago Dei, but also the Christian understanding of the
beginning of life at conception. For Cherry, imago Dei is a necessary concept to

20

integrate into one’s own moral judgement that leads to the development of morally
sound medical decisions. Also, imago Dei manifests in Cherry’s rejection of any
categorization of desirable and undesirable traits. For Cherry, all elements of an
individual, whether desirable or not, are representations of God. The understanding
of the beginning of life informs Cherry’s rejection of prenatal diagnosis that can lead
to abortions and family planning methods that he understands to be selecting a
promising embryo and “killing” the others. The blending of the two elements,
beginning of life and imago Dei, continues within Cherry’s rhetoric and specific
usage of “children” instead of fetus or embryo. Cherry disapproves of individuals
judging characteristics as desirable or undesirable, because each and every
characteristic is made in the image of God. Here we can see Cherry’s understanding
of embryos and fetuses as already independent lives and souls and the removal of
them as “killing”. Cherry’s disapproval of genetic editing is based both in the
Christian understanding of the beginning of life and imago Dei and Cherry’s
understanding of genetic editing and possible endings of pregnancies as inflicting
harm on these lives.
In a letter commenting on current scientific advancements, the Vatican
International Theological Commission addresses genetic technologies and
specifically the genetic editing of humans. Here the Vatican relies heavily on the
concept of imago Dei as the essential nature of humans to inform a rejection of
genetic editing based on a failure to value that human qualities are all made in the
image of God. In this letter the Vatican positions imago Dei as the center piece for its
framework and explains it as the key to a biblical understanding of “human nature
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and [key] to all the affirmations of biblical anthropology in both the Old and New
Testaments. For the Bible, the imago Dei constitutes almost a definition of man: the
mystery of man cannot be grasped apart from the mystery of God” (Vatican
International Theological Commission, 2004). For the Vatican, this defining
characteristic of humans informs its opinion against the genetic editing of humans
and is further explained when the Vatican writes, “A right to dispose of something
extends only to objects with a merely instrumental value, but not to objects which are
good in themselves, i.e., ends in themselves. The human person, being created in
the image of God, is himself such a good” (Vatican International Theological
Commission, 2004). Imago Dei is an element of being human that sets humans
aside from other objects on earth. The Vatican’s rejection of genetic editing is
founded in the concept of imago Dei which informs the conclusion that human
genetic modification would be an infliction of harm as it would be changing
intrinsically good characteristics.
On the other hand, the notion of the full expression of an identity that is made
in the image of God is utilized in support of genetic editing. Although contradictory to
the Vatican’s previous rejection of genetic editing, within the same letter the Vatican
advocates for an acceptance of genetic editing as a method to help people fully
express their identity which may be obstructed by congenital diseases. The
Vatican’s very clear supportive stance on the genetic editing of congenital diseases
stands out against the many Christian campaigns against finding a Down Syndrome
“cure” (Curtis, 2011;)Knight, 2017;)Peoples, 2017). In this letter the Vatican claims
that congenital diseases such as Down Syndrome negatively affect the identity of a
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person both physically and mentally. Thus, the Vatican advocates for genetically
altering these conditions as the modification would “help the individual to give full
expression to his real identity which is blocked by a defective gene” (Vatican
International Theological Commission, 2004). This particular framework positions
Down Syndrome and similar genetic conditions as barriers that constrict the ability to
fully express a person’s God given identity. In this scenario, genetic editing acts as a
mechanism to remove the “defective gene” and therefore, reduce the harm caused
by the disease preventing a God-given right to a full expression of identity. Although
this is contradictory to other statements given by the Vatican, this support of the
genetic editing of congenital diseases highlights the possibility of the Christian
support of genetic editing when it is understood as a reduction of harm.
The concept of imago Dei is a major factor in many Christian arguments
about genetic technologies, however the arguments each utilize different details of
imago Dei to support or reject genetic editing. Cherry’s argument centers in on the
concept of humans being made in the image of God; in his view, forgetting this
essential truth leads to the development of morally corrupt stances on reproduction.
These stances would then lead to medical decisions that Cherry believes are
harmful to current and future lives such as abortion and editing undesirable genetic
characteristics. The Vatican’s anti-genetic editing argument addresses genetic
editing by specifying that changing an essential part of a human ceases to
acknowledge the holy nature of humans being made in the image of God and would
thus be inflicting harm on the individual. The Vatican’s pro-genetic editing argument
positions congenital diseases as barriers to a full expression of an imago Dei identity
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and genetic editing as a mechanism to help reduce the harm cause by those
diseases and allow full expression of identity. Although all three arguments
incorporate the concept of imago Dei, their rejection or support of genetic editing is
due to how imago Dei informs their judgement on what exactly is inflicting or
reducing harm. For example, a condition may be considered to inflict harm on an
individual if they understand this condition to be preventing the individual from fully
living out their true identity. However, if the individual understands all characteristics
as being made in the image of God, then any modification of that condition could be
considered a disrespect or mistreatment of something truly imago Dei.

Stewardship
Within the Christian understanding of the hierarchal Creator-creation
relationship, humans are entrusted with the responsibility to be stewards. This role
and its application in today’s scientifically advanced world has allowed for more
variety of stances on genetic editing. Two common biblical passages that inform the
Christian tradition on stewardship are Luke 12:41-48 and Matthew 25:14-30. The
Luke parable informs on how to be a good steward through an analogy of a master’s
manager in charge of his servants and how to care for them. The passage from
Matthew is the parable of the Bags of Gold in which a master gives his servants
bags of gold in which the good and faithful servant invested his money so that when
the master came back to collect the gold he gave more than was initially allotted to
him. However, the “lazy servant” hid the money in a hole so that when the master
came back he only gave back the same amount initially given to him. Both of these
stories provide messages of taking care of God’s creations and of cultivating God’s
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gifts so they are more abundant in the future. In a letter from the United States
Conference of Bishops on how to be a Christian steward, stewardship is explained
as “respect for human life—shielding life from threat and assault, doing everything
that can be done to enhance this gift and make life flourish” (United States
Conference of Catholic Bishops, 2006, p. 451). This understanding of stewardship
within the greater Creator-human relationship is relevant to Christian genetic editing
discourse, as it can influence individuals’ judgements on genetic editing and whether
or not it is proper care of God’s creation. This section will analyze three different
Christian arguments about genetic editing that utilize stewardship in their claims that
genetic editing either harms individuals and is therefore not proper stewardship or
helps protect and enhance individuals and is therefore appropriate stewardship.
The use of stem cells within genetic research and clinical applications of
genetic technologies is a Christian moral dilemma that calls into question whether
humans are fulfilling the role of stewardship. Public Health scholar Stephen Modell
attempts to situate genetic editing within the Christian understanding of stewardship
in regard to its usage of stem cells. Modell understands the acquisition of stem cells
to be from either germline cells of aborted fetuses or fertilized eggs not used during
in vitro fertilization and considers both methods as including the “death” of a fetus or
embryo. The choice to use the word “death” when describing the termination of
fertilized eggs exemplifies elements of the Christian understanding of the beginning
of life fueling the argument; for Modell the fertilized egg, embryo and fetus are all
alive. Thus he claims that “downstream use of stem cells wraps the user in a state of
complicit guilt, because the only way the stem cells could be used is at the earlier
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expense of an embryo or fetus” (Modell, 2007, p. 174). For Modell, any use of stem
cells is intimately connected to the death and harm of lives. Since genetic
technologies can rely on stem cells for their research, the clinical use of genetic
editing cannot be separated from its harm to lives; thus, positioning it as counter to
the stewardship role awarded to Christians.
Within the discussion of whether current genetic technologies fulfill or oppose
the Christian call to stewardship, the care of not only the current and immediate next
generation but all future progeny are included. Philosophy and Biomedical Ethics
scholar James Delaney explains the Catholic Church’s position on genetic
engineering when writing that the Catholic Church distinguishes “between somatic
cell therapy and germ line cell therapy, and prohibits the latter, because of two
reasons: its potential to harm progeny and its use is in conjunction with in vitro
fertilization” (Delaney, 2009, p.33). Although this may seem like a rejection of
genetic technology as we currently know it, Delaney goes on to describe the very
concrete changes within genetics that would allow for Catholic approval:
Should the current state change in the following two respects, 1) risks to
progeny are reduced so as to be out- weighed by likely therapeutic benefits,
and 2) the subjects involved in the germ line therapy (either gametes or early
stage embryos) do not affect persons coming into existence through a morally
licit act (the conjugal act between a husband and wife), the Church’s position
on germ line therapy would likely be that it is morally permissible. (Delaney,
2009, p.33)
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Delaney applies the call to stewardship to all current and future progeny by arguing
that when the benefits of genetic editing outweigh the risks to currently non-existing
lives, then germline genetic editing will be closer to being accepted by the Catholic
Church. In addition, elements of the Christian understanding of the beginning of life
complicate the Catholic Church’s position on genetic editing. It seems that for
Delaney embryos or fetuses not formed through conjugal act, such as through in
vitro fertilization, are in fact not considered alive; this understanding is drawn from
Delaney’s second condition about persons coming into existence through a morally
licit act. Therefore, the use of them can possibly be warranted because there is
technically not harming of life. Throughout the article Delaney continuously critiques
germline editing, which hints at Delaney not rejecting somatic gene editing as it
would not entail the death of embryos or harm to future progeny. The current
rejection of existing mainstream genetic technologies and the presentation of
qualifications for potential acceptance of future genetic technologies both utilize the
potential harm of progeny and harm of current lives as major factors for evaluation;
thus, potential harm of progeny and embryos/fetuses should not be considered a
“dead end” for genetic advancements but rather considered an avenue for potential
acceptance.
Although stewardship has been used as criteria for the rejection of genetic
editing and the proposal of changes to current methodologies, it can also be used as
a framework to advocate for the usage of genetic editing. Rooted within a Christian
pro-life framework, political scientist and biologist Brendan Foht focuses on the
stewardship of fetuses and advocates for the usage of genetic editing as it can
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increase the chances of survival for a fetus. Foht positions the analysis of genetic
editing in contrast to abortions that are informed by prenatal screenings when
writing, “Morally speaking, editing the genes of embryos rather than destroying them
would be a step in the right direction” (Foht, 2016, p. 12). Foht considers genetic
editing as a preferable alternative to the abortion of fetuses with unwanted
characteristics. Here elements of the Christian concept of the beginning of life inform
Foht’s understanding that embryos are in fact alive and the termination of them is
“killing”. In conjunction, Foht’s analysis of the harm in each case facilitates his
approval of genetic editing as it would in actuality reduce the harm of a life that
would have been ended otherwise.
The Christian duty of stewardship is called upon throughout debates over the
use of genetic technologies. Although God’s call for humans to be stewards is
relatively agreed upon within communities, what exactly this stewardship calls for is
not standardized. For Modell, stewardship, informed by the Christian understanding
of the beginning of life, includes the protection of embryos and fetuses which allows
for Modell to reject the use of genetic editing because it is a downstream use of stem
cells and the “death” of embryos and fetuses. Delaney utilizes the concepts of the
beginning of life with the conjugal act and stewardship when concluding the current
germline genetic technologies both harm future progeny and utilizes “killed” embryos
and fetuses; instead, Delaney proposes utilizing embryos not created via conjugal
act and developing genetic technologies where the benefit will outweigh the risks of
harm to future progeny. Foht also applies stewardship to fetuses but concludes that
genetic editing would technically be a form of care and reduction of harm if it
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increases the chances of survival. Intricacies within Christian stewardship such as
caring for potential progeny, embryos, and fetuses allow for both Christian
acceptance and rejection of genetic technologies; however similar to previously
identified trends, the understanding of genetic editing as potentially protecting or
reducing the harm of lives allows for a Christian justification of genetic editing.
Conclusion
There is a common misunderstanding that a unanimous Christian rejection of
genetic editing exists; instead, there is a medley of rejections and acceptances with
contradictions that highlight four major tension zones: the beginning of life, the
Creator-human relationship, imago Dei, and stewardship. Aside from which of these
different Christian concepts are utilized, the arguments within the Christian genetic
editing discourse differ from each other depending on the understanding of genetic
editing in regards to harm. All of the arguments that understood genetic editing to be
inducing harm rejected genetic editing, while the arguments that supported genetic
editing understood it to be a form of reducing harm. This judgement-call on whether
or not genetic editing is causing or reducing harm is rooted in the individual’s
categorization of the genetic condition as being imago Dei or a barrier from fully
expressing one’s imago Dei potential. A combined understanding of what the tension
zones are and the determining harm factor is extremely important for geneticists, as
it can help them identify possible avenues to explore and then develop genetic
technologies that may be accepted and used by more individuals. With this chapter
locating the tension zones and harm factor amongst the current Christian discourse,
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these tension zones will be analyzed for how they can specifically be useful in the
development of new genetic technologies.
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CHAPTER TWO.
FRUITFUL GENETIC EDITING RESEARCH PATHS
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Introduction
A Christian married couple has been trying to have a child and participate in
the Christian creation of life, however they were told by their physician that both of
them are carriers of a congenital lethal disease. The couple is confused because
they would still like to fulfill their marital calling to procreate but also fulfill their call to
stewardship and care for their child’s health, protect them from a lethal disease that
could potentially kill them. One of the most common paths couples could chose is in
vitro fertilization (IVF), which fertilizes a couple egg samples with sperm in petri dish
and after enough division cycles, the healthiest or in this case the one without the
disease gene is selected and the rest are discarded. However, this would not be a
possible path for this couple as it would involve the ending of a life under a particular
Christian definition (fertilized egg) and it would omit the conjugal act, also central to
some Christian understandings of the production of life. Genetic editing is a potential
path that the couple could consider as a way to possibly secure that their future
progeny would not suffer from this condition. Genetic editing is the modification of an
individual’s genetic information (DNA) in efforts to modify a genetic characteristic or
trait of theirs. Although genetic editing of humans is a relatively novel study, there
have been recent major strides in the research of clinical application of genetic
editing of human embryos. For example, in 2017 embryologist Shoukhrat Mitalipov
successfully modified a human embryo that originally carried a heart defect gene
(Ma et al., 2017). Mitalipov’s team claims that this is a potential mechanism that
would help “rescue mutated embryos that would otherwise be screened out of in
vitro fertilization (IVF) procedures” (Servick, 2017). However, this specific method

32

would still not accomplish the Christian goal of ensuring the conjugal act in the
creation of life. Within the Christian discourse of genetic editing, there is a concern
regarding the necessity of the conjugal act as a mandatory precursor to the creation
of life. As identified in the previous chapter, the Vatican claims that the conjugal act
must not be replaced by but aided by reproductive technological techniques (Vatican
International Theological Commission, 2004). The inclusion or reliance on the
conjugal act within genetic editing research poses to hurdles. It does indeed
complicate the experimental logistics when transitioning to human subjects,
compared to simply mixing sperm and eggs in a petri dish. Secondly, scientists tend
to look at efficiency and reliability when proposing new clinical methods; relying on
the conjugal act is not seen as the most direct path. Thus, there exists a scientific
need to fulfill a deficit within the research community that lacks major consideration
of possible techniques that include the conjugal act. Research in these areas that
would prove useful to and accepted by many individuals would include epigenetics,
somatic cell genetic editing, and in vivo genetic editing research.

Epigenetics
As previously explained in the last chapter, the Christian concept of
stewardship, which calls for individuals to take care of and nurture God’s creation,
fuels a call to protect current and future progeny from harm. Attending to the
Christian concern about harm to progeny and the Christian calling of stewardship,
Epigenetics is a specific field of genetics that focuses on hereditary gene functions
that are not rooted in DNA sequence alterations; in other words, it focuses on
structural changes that may affect the cell’s access to DNA via physical markers
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such as the extent of tight coiling of the genetic material. In a 2008 epigenetics
conference, an epigenetic trait was defined as “a stably heritable phenotype
resulting from changes in a chromosome without alterations in the DNA sequence”
(Berger, Kouzarides, Shiekhattar, & Shilatifard, 2009, p. 781). These epigenetic
states of the genome can affect the accessibility of the genome and its expression.
The three major epigenetic modifications are DNA methylation, histone modification
and non-coding RNA- associated gene silencing. It is commonly understood that
possible sources of epigenetic modifications can include one’s environment and diet.
With epigenetics as a “buzz” field surfacing on the pages of multiple health blogs to
scholarly scientific conferences, epigenetics has been incorporated into a diverse
public discourse; it complicates the general understanding of hereditable information
as predetermined and not affected by one’s own life. Although not the explanation
for many genetic conditions, the epigenetic explanation of many gene expression
conditions produces a sense of controllability regarding genetic conditions. Not only
can lifestyle factors negatively affect gene expression, but certain lifestyle changes
can instead benefit genetic expression and serve as epigenetic therapy that is not
affecting the DNA itself. This ability to possibly “fix” one’s condition without having to
physically change the DNA can facilitate individuals to feel more autonomous and
capable of independently helping their condition and possibly no longer passing on a
negative epigenetic marker onto their progeny.
To investigate common lifestyle variables and their possible epigenetic
effects, studies have investigated both environmental and dietary variables.
Regarding the environment, pollution is a major concern as an epigenetic
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modification initiator of histone acetylation. Dinga R et. al investigated this
relationship between pollution and histone acetylation in mice model and claims that
it can be used to help further elucidate the relationship between air pollutants and
lung disorders (Ding et al., 2016, p. 170). Pertaining to diet, a recent study
concluded that a ketogenic diet can help alleviate the a deficiency of chromatin
opening common in Kabuki syndrome (Benjamin et al., 2017). Here, diet is used as
a form of epigenetic therapy to help reduce the existing epigenetic condition of the
genome in mice with Kabuki syndrome. A research group focusing on acute myeloid
leukemia (AML), has identified epigenetic mutations that result in a pre-leukemic cell
state (Wouters & Delwel, 2016). These researchers then identified that epigenetic
therapy to this pre-cancerous state could help reduce the cases of this disease.
These studies are all pre-clinical and producing vital information for future clinical
epigenetic therapy. Current human epigenetic clinical trials include the development
of histone deacetylase (HDAC) inhibitors for cancer therapy and neurological
disorder treatment (Marks & Xu, 2009)(Kazantsev & Thompson, 2008). These
inhibitors affect the chromatin packaging and expression of genes in charge of cell
cycle events that are usually abnormally regulated in cancer cells (J. M. Wagner,
Hackanson, Lübbert, & Jung, 2010).
Although these clinical and pre-clinical trials show very promising results for
the efficiency of epigenetic therapy, the easy reversibility of epigenetic changes
lends itself to both the risk and benefit of the clinical use epigenetics as therapy. If
an unintended epigenetic modification does occur during a treatment, it is very
possible that it could be easily reversed. However, the opposite case of an
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epigenetic beneficial modification being reversed could be considered a risk. Is the
efficiency of epigenetic therapies reduced because of this reversibility and how long
would therapy effects last?
In regards to the specific Christian understanding and moral decision about
epigenetics, very few have published any specific opinions on it. As noted in chapter
1, one published Christian understanding of epigenetics understands the epigenetics
markers as heritable effects of sin that can act as pre-dispositions to sin for future
individuals (Beck, 2007). Due to the overall lack of published Christian arguments
about epigenetics, I will focus on how epigenetic research and therapy might interact
with the existing Christian themes and concerns of stewardship and prevention of
harm.
With its ability to help treat potential hereditary health complications and since
epigenetic modifications are technically not changing the DNA material itself,
epigenetic therapy appeals to the Christian theme of stewardship and concern about
harm to progeny. Epigenetic therapy would allow individuals to remove/reverse
harmful epigenetic markers from their genetic material without actually changing the
DNA and thus without overstepping the Creator-human boundary. Such treatment
would allow Christian individuals to “take care” of their future progeny and thus be
stewards of God’s gifts. In addition to helping fulfill the Christian concern regarding
the care and prevention of harm to future progeny, epigenetic therapy would address
the Christian understanding of genetic conditions, discussed in the previous chapter,
as linked to environmental stressors that are in fact resultant from the individual’s
relationship with God (Beck, 2007, p. 67). In this case epigenetic therapy would be
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addressing a physical component of a person’s hereditary material, but would still
appeal to Christian epigenetic and environmental understanding of certain conditions
rather than purely DNA based.
Although there is an abundant amount of epigenetic research already being
conducted and in the pipeline, an interesting epigenetic variable that would be
important to understand more comprehensively through more research is the
longevity of certain epigenetic mutations. This understanding of how long epigenetic
modifications last before being reversed or even turned into something else can be
important in deciding whether or not epigenetic therapy is clinically worthwhile.

Somatic gene editing
Another potentially productive genetic editing avenue to research is somatic
gene editing, which appeals to the Christian stewardship call to prevent harm to
progeny. As discussed in the previous chapter, somatic cells differ from germline
cells in regards to heritability; somatic cells are not heritable and comprise the far
majority of an organism. In theory, the modification of a somatic cell could affect a
variety of somatic cells targeted but would not be transmitted to future offspring, as it
would not be modifying any germline cells. In this section I will look at both current
practices of fetal and adult somatic cell editing, the risks involved, and how they can
alleviate some Christian concerns.
Fetal somatic cell editing is an in utero method and has been identified as a
potential “prenatal prevention and permanent correction of disease manifestation
particularly for early onset diseases” (Coutelle & Rodeck, 2002, p.670). Coutelle
and Rodeck both identify in utero fetal somatic gene therapy as not only an excellent
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preventative medicine option, but also an excellent option for individuals who find
themselves having to consider pregnancy termination following the diagnosis of a
severe genetic disease. The option of in utero fetal somatic gene therapy would
allow them to instead edit this unwanted and harmful genetic disease, while still
allowing them to keep the same fetus alive and not have as much of a pressure to
consider abortion. Douar et al. investigated and solidified the role fetal somatic gene
therapy can have in the prevention of irreversible perinatal diseases (Douar, Themis,
& Coutelle, 1996, p. 633).
A more recent study investigated easier ways to treat congenital
diaphragmatic hernia, a condition that ultimately can hinder proper lung formation.
Currently this disease is treated via a physically invasive endoscopy of the fetal
trachea, which can be risky when done on delicate fetal membranes. Using the
sheep as their model organism, the researchers concluded that sheep fetal trachea
can be accessed and genetic therapy can be administered to it by vectors via
percutaneous ultrasound-guided injections (David et al., 2003, p. 385). Basically, the
researchers are proposing that an improved method to the fetal endoscopy would be
to inject genetic editing material into the fetal trachea via a tiny needle and that the
genetic editing material will be guided to the target area via specific wavelengths
applied to the subject. This finding is exciting as it points to a near future where
individuals will be able to “better protect” their progeny through genetic editing
methods, as they could potentially be less prone to physical complications such as
membrane rupture. In addition to research of fetal somatic gene editing, there has
been lots of research in adult somatic gene editing.
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Current research and clinical interest in adult somatic gene editing ranges
from understanding the nature of cancer to metabolic diseases. In order to more
comprehensively understand cancer, Sánchez-Rivera et al. performed a rapid
modelling of cooperating genetic events in cancer through somatic gene editing
(Sánchez-Rivera et al., 2014, p. 428). This modelling allowed them to better identify
which mutations could be causing the tumorigenesis within a mouse model. In this
study, the research team looked at common identified cancer-related genes within a
lung-cancer model and systematically activated or deactivated them with genetic
editing and observed its effect on tumorigenesis. The hope of this study is that a
dense catalogue of cancer genome mutations can help identify early stages within
the cancer timeline and subsequently be used to develop therapies for individuals
(mostly non-fetus) with cancer. Since a majority of cancers develop later in life, the
applications of this therapy would have more opportunities within adults rather than
only simply in fetuses. In regards to somatic gene editing’s role in understanding
metabolic diseases, it allows for an easier method of modeling. Currently
researchers model metabolic diseases by genetically editing germline cells and
breeding said cells to produce metabolically diseased model organisms. However,
Jarrett et al. explored the possibility of using somatic editing to simply edit already
existing adult individuals so that they express the desired mutation (Jarrett et al.,
2017, p. 1). This method allows for an easier research method that opens up paths
towards more feasibly research of metabolic diseases and therapies.
Somatic gene editing has clearly allowed for groundbreaking and helpful
understandings of medical conditions and the nature of cells. The clinical use of
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somatic gene editing allows for specific non-hereditary genetic editing that lacks the
same risk to progeny that accompanies germline editing. However, this usage does
come with some risks that are important to identify. First, although somatic gene
editing in theory should not be transmittable to offspring, there is still an underlying
risk of germline transmission. A research team from the Department of Obstetrics
and Gynecology or Bern University Hospital, explains this risk as “Because vector
integration into germ cells, if it occurs, is likely to be random, an integration event
could potentially have disastrous effects for progeny conceived from such a germ
cell” (A. M. Wagner, Schoeberlein, & Surbek, 2009). This same research team
identifies another potential risk, maternal spread: “the possible risk of vector spread
from the fetus to the maternal body, although the number of layers may not be the
only factor determining placental permeability” (A. M. Wagner et al., 2009). Although
current studies suggest this risk is relatively low, I agree with this research team in
the necessity for more research in order to fully understand maternal cell
transduction (Ye, Gao, Pabin, Raper, & Wilson, 1998). In my opinion, this potential
risk to the mother seems like it would not sit well with the general and Christian
population. However, when analyzing the Christian discourse of genetic editing,
there are no major arguments pro or against genetic editing addressing risk to the
mother. This then points to a seeming lack of attention towards women’s health in
regards to genetic editing within the Christian discourse.
In regards to the relationship between further development of somatic genetic
editing and Christian discourse of genetic editing, somatic genetic editing could
potentially help fulfill the Christian concerns regarding the safety of future progeny
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and the need for the conjugal act in the creation of the new life. As highlighted in the
previous chapter, the Catholic Church distinguishes “between somatic cell therapy
and germ line cell therapy, and prohibits the latter, because of two reasons: its
potential to harm progeny and its use is in conjunction with in vitro fertilization”
(Delaney, 2009, p.33). In conjunction with the general understanding of a low
germline transmission (Ye et al., 1998), somatic genetic editing allows for a safer
method of treating genetic conditions without unforeseen future effects on offspring
that are potentially possible in germline editing. With further research, adult somatic
gene editing techniques could be developed that solidified the editing of cancerous
tumors in adults via cancer cell targeted genetic editing materials, whether through
ultrasound or other guiding mechanisms. In addition to appealing towards the
Christian stewardship element of prevention of harm, somatic gene editing can
appeal towards the Christian necessity of the conjugal act when procreating. The
option of editing the somatic cells of a fetus, allows a Christian individual to both
create life via the conjugal act but also, if the individual had been considering the
pregnancy termination, this would allow another option that would be more accepted
by the Christian public.
In addition to appealing to Christian concerns, somatic genetic editing
appeals to bioethical and general medicinal goals. First, the ability to genetically edit
the somatic cells of individuals, and specifically adults, situates itself well within
bioethical concerns about agency. With adult editing, there is clearly more agency
provided towards the individuals, in contrast to genetically editing the somatic cells
of fetuses. The somatic cell editing of fetuses, on the other hand, seems to address
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the concerns of the medical goal of pushing towards a future of preventative
medicine. In 2002, 8 major healthcare member organizations, ranging from doctors
to pharmacists, collaborated to implement healthcare objectives titled the “Clinical
Prevention and Population Health Curriculum Framework” as a major effort to help
the United States healthcare system shift from one of diagnostics/curative to one of
preventative(RK Riegelman & Garr, n.d.). Somatic cell editing appeals to this model
of preventative medicine, as it allows for the treatment of potential at risk cells before
a major disease develops.
In regard to Christian, general medical, and bioethical concerns, further
somatic genetic editing would prove productive in the development of more
acceptable and therefore, usable forms of genetic editing. Further research into the
amount of germline transmission present within somatic editing treatments would
help elucidate the amount of potential harm to progeny there actually is; this can
then increase the amount of information individuals have when deducing their
potential medical paths when faced with genetic conditions. In addition, there must
be further research into the potential maternal risk during fetal editing, both to
increase the agency of the women undergoing this procedure but also to help further
build a future within medical and Christian discourse that commonly incorporates
women’s health and concerns.

In vivo genetic editing
Not only is the type of genetic information being edited important, but also the
mechanism that it is accessed and edited is just as pertinent in regards to Christian
acceptance. When it comes to the editing of progeny, whether before or after
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conception, the method of fertilization utilized is important as there is a Christian
need for to maintain a tradition understanding of conception through the marital
conjugal act. The Christian pushback against some clinical fertilization techniques
such as in vitro fertilization (IVF) are rooted in this exact concern that rejects the
fertilization of the egg in a laboratory petri dish and advocates for the couple to
instead procreate via heterosexual intercourse. This is relevant to this discussion of
genetic editing as scientific and specifically genetic studies are commonly one of
three types: in vivo, in vitro, and in silico. In vivo experiments are carried out within a
living organism and is capable of producing a greater understanding of the total
effects of a variable on the entire organism, including its total interaction with other
body variables. In vitro experiments are the opposite of in vivo and are not
conducted within a living organism. These studies produce a less comprehensive
understanding of the particular independent variable’s effect as it does not
incorporate organismal conditions as well as in vivo studies. However, in vitro
studies benefit from not having as much of a risk of harming actual organisms and
are more easily reproducible. In vitro techniques are common amongst reproductive
scientist in regards to egg/sperm extraction and in vitro fertilization, because it can
provide a sterile, easily observable and controllable environment. In silico refers to
studies performed using a computer software simulation and an abundant database.
This is a relatively newer form of experiment that is commonly used as a primary
investigation of a variable or mechanism and can help construct possible in vivo or in
vitro studies of the same variable. In genetics, in silico studies are now ever present
in gene expression analysis(Murray, Doran, MacMathuna, & Moss, 2007). With this
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background of current experimental approaches, this section focusses on in vivo
genetic editing of eggs (fertilized and non-fertilized) and sperm and analyzes it as a
potential productive avenue of clinical genetic editing that will be more accepted by
Christian users by appealing to the inclusion of the conjugal act.
Although not currently clinically used, in vivo genetic editing locates itself in a
variety of contemporary research studies. What does this current in vivo genetic
research look like? In 2015, Lukas Dow et al. published a study that examined
inducible in vivo genome editing with CRISPR-Cas9 in mice and claims that an
“inducible CRISPR (iCRISPR) system can be used effectively to create biallelic
mutation in multiple target loci and, thus, provides a flexible and fast platform to
study loss-of-function phenotypes in vivo”(Dow et al., 2015, p. 390). Dow’s team
essentially provides a viable approach to rapid and scalable studying of gene
functions in vivo. Also using mice as their model organism, in 2011 Hojun Li et al.
study how in vivo genome editing can restore hemostasis, the stopping of bleeding,
in hemophilia, a genetic disorder that reduces an organism’s ability to form blood
clots and terminate bleeding. Before this study, the use of zinc finger nucleases
(ZFNs) was used in genome editing in vitro, however this research wanted to
explore its efficiency in vivo. By examining the effective level of gene targeting and
concluding that it could effectively correct the hemophilic prolonged blood clot times,
they were able to claim that this “ZFN-driven gene correction can be achieved in
vivo, raising the possibility of genome editing as a viable strategy for the treatment of
genetic disease”(Li et al., 2011, p. 217). This research team’s finding show that ZFN
can not only be used in vivo, but that it can efficiently bind the new desired gene to

44

the targeted location with the necessary consistency and efficiency to be a clinically
viable method. With studies like the ones presented showing the viability and
efficiency of in vivo genetic editing and the beneficial clinical applications, its future
clinical use on humans is near and the risks of the clinical human application are
important to consider.
With in vivo genetic editing, there is an inherent risk that accompanies the
therapy being done within the living organism. The off target of gene editing is a
measurement of unwanted genetic manipulations of the genome. This means that
possible unwanted mutations could include the wrong gene being edited or the
wrong cell/tissue type being edited. In vivo, if there is a mistake and a different gene
is modified or if the wrong cell type is edited, it can possibly affect multiple
unintended regions of the body. For example, if one wanted to target a specific gene
and there was another gene that had a similar coding region to the target, the editing
mechanism has a risk of binding to the unintended region. This would then result in
an unintended effect, commonly called the off-target effect. If an individual wanted to
target a controlled section of the body such as the eggs but the mechanism used
traveled to another region and edited that, there could potentially be unintended
effects. In contrast, in vitro editing mistakes could not travel to and affect other
regions and these mistakes could be easily identified and those affected cells could
simply not be used.
Although in vivo genetic editing research is very much present and abundant
today, a majority of the research focuses on somatic cell editing, such as the cancer
and metabolic disease studies discussed earlier. I propose that shifting some
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attention to in vivo germline genetic editing would prove fruitful in efforts to produce
more accepted genetic editing techniques. The next section will focus on in vivo
germline genetic editing and investigate its efficiency compared to in vitro genetic
editing. In vivo germline editing could manifest itself as editing the sperm or eggs
themselves, or editing the cells that produce sperm and eggs. In vivo genetic editing
of germline cells would potentially address the Christian concern for the conjugal act
in the creation of future progeny, as it would allow for the editing of egg and
sperm/sperm producing cells within an individual prior to the conjugal act. These
techniques could be helpful for individuals who are concerned about a need for the
conjugal act but want to fulfill their role as stewards and protect their progeny via
protecting them from a certain heritable disease.
Conclusion
With the previously identified tensions zones within Christian discourse of
genetic editing in mind, possible paths of genetic research can be identified to help
develop more accepted genetic editing practices (epigenetics, somatic gene therapy,
in-vivo genetic editing and adult genetic editing) that appeal to the Christian
stewardship goal of prevention of harm and the need for the conjugal act in the
creation of new life. Amongst the analysis of possible research paths, I identified a
concerning lack of attention towards somatic genetic editing’s potential risk of
maternal transduction, when the editing mechanism vector spreads from fetus to
mother. Although this lack of concern allows for more potential genetic editing paths
that the Christian body could potentially accept, it should not go unquestioned.
Further inquiries as to why exactly the Christian community is not worrying about the
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maternal body when considering risk assessment should be considered. The next
section will examine current data on off-target effects of CRISPR-Cas9 genetic
editing and propose an experiment to understand if the off-target affects will change
when in vivo verses in vitro.
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CHAPTER 3.
AN ANALYSIS OF IN VIVO AND IN VITRO CRISPR-CAS9
EFFICIENCY
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Introduction
Today, the pages of online health blogs to Time Magazine are filled with the
general public in discussion of genetic editing. The focus of these conversations
varies between bioethical concerns, efficiency, and safety for clinical application on
humans. As discussed in the previous chapters, since the launch of CRISPR,
genetic editing has been a hot topic within Christian communities; a major Christian
concern with genetic editing and its usage is the lack of the “conjugal act” in current
genetic editing of future progeny. For example, commonly paired with genetic editing
of embryos is in vitro fertilization (IVF), which forgoes an explicit need for the
heterosexual sex, but instead is efficiently accomplished with the fertilization of an
egg with a sperm sample in a laboratory setting. In efforts to develop more forms of
genetic editing that communities are comfortable with and therefore allow genetic
editing to be more accessible to these patients, I propose that comparing the
efficiency of in vivo and in vitro CRISPR genetic editing will help form a basis for
further research and possibly development of in vivo germline editing. This form of
genetic editing is the topic of analysis for this study, as it relieves a Christian concern
about the need for the “conjugal act” in the creation of new life.
In order to attest to the efficiency of in vivo CRISPR genetic editing in
comparison to in vitro, this study will analyze current research on in vitro genetic
editing and suggested optimizations and then apply this information in the
development of the experiential design. This proposal will offer a study that will
analyze both on-target and off-target mutations, in addition to overall efficiency, in
both in vivo and in vitro treatments.
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On-target mutation efficiency
In order to test whether or not a genetic editing technique is in fact editing the
intended sequences, the on-target mutation efficiency must be measured. Currently
there are a variety of methods to do this: mismatch cleavage assay, high-resolution
melting analysis (HRMA), heteroduplex mobility assay by PAGE, cleaved amplified
polymorphic sequences (CAPS) analysis, Sanger sequencing, amplified fragment
length polymorphisms (AFLP), and Fluorescent PCR-capillary gel electrophoresis
(Zischewski, Fischer, & Bortesi, 2017). Each method has its own benefits and
disadvantages but generally concern whether or not it can detect small indels, large
indels, and substitutions. The methods that miss large indels are: HRMA and
heteroduplex mobility assay by PAGE, while AFLP fails to detect small indels and
Fluorescent PCR-capillary gel electrophoresis fails to detect substitutions. Although
many kinds of mutations could be incorporated by HR depending on the donor DNA,
small indels from NHEJ repair and substitutions from HR using a donor template are
more common than large indels. This characteristic is because the CRISPR system
relies on endogenous double-strand break repair pathways. Thus, HRMA and/or a
targeted sequencing method could detect the mutations.
HRMA is an analysis method that concentrates on a target region, amplifies it
with a fluorescent PCR and analyzes it via melting curves (Zischewski et al., 2017).
This technique is dependent upon the fluorescence loss when the dyes are no
longer attached to the dsDNA during thermal denaturation. These melting
temperature curves are utilized to identify the specific nature of the allele
(homozygous/heterozygous mutant/wildtype); the shifts of the curves represent a
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variation of nucleotides (Thomas, Percival, Yoder, & Parant, 2014). In order to
produce an optimal HRMA with high resolution, the amplicon size is suggested to be
around 100 bp (Thomas et al., 2014, Zischewski et al., 2017). The same
amplification products could later be used for other analysis methods because
HRMA does not alter the sequence of the amplicons. If for some reason a large indel
is expected, to account for the limitation of HRMA not detecting large indels, AFLP
can be used to detect these larger mutations. The
Some decreases in on-target efficiency can also be attributed to
nonhomologous end joining (NHEJ) of sequences rather than the preferred method
of donor DNA integration through homology-directed repair (HDR). In order to
combat this efficiency deficit, I will utilize single-stranded donor DNA (ssDNA)
instead of the common double-stranded DNA (dsDNA) as ssDNA has been shown
to increase HDR efficiency in Cas9-mediated gene editing in human cells
(Richardson, Ray, DeWitt, Curie, & Corn, 2016). The donor ssDNA is developed to
be of optimal length that is complementary to the 3’ terminus of the cleaved DNA
strand that is complementary to the target strand. This optimal donor ssDNA has
been shown to increase HDR rates to up to 60% and should be incorporated within
protocols when developing and/or investigating efficient methods of CRISPR genetic
editing.

Off-target effects
Ways to detect
The rate of off-target mutations is an essential factor dictating the potential
usage of a certain method of genetic editing. For the purpose of measuring the off-
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target effects, there are both biased and unbiased methods of varying sensitivity.
Biased approaches look at specific predicted sites, while unbiased approaches look
at the whole genome. For this study, I propose to use a targeted sequence
amplification, a popular biased method that amplifies and sequences previously
identified segments that may contain off-target sites. These potential candidates for
off-target mutations can be identified via sequence similarity to the Cas9 guide RNA
sequence. Sequence analysis of amplified candidate regions can be performed via
Sanger sequencing or next generation sequencing (NGS). Sanger sequencing
becomes a bit impractical when there are many potential segments to sequence.
Although the amount of off-target sites vary widely based off of the identity of the
gRNA, the number of off-target mutations can range from 0-150 (Zischewski et al.,
2017). Digenome sequencing is an unbiased technique which utilizes Cas9 and
sgRNA in vitro to scan for potential off-target sites that can be used in the targeted
sequence amplification, later sequenced via NGS (Zischewski et al., 2017). This
method uses the combination of cell-free genomic DNA, Cas9, and sgRNA to
identify both the target and off-target sites that are cleaved and measures the
frequencies of unintended indels. Digenome sequencing has many benefits that
include identifying off-target sites whose mutations occur at rate below 0.1% (Kim et
al., 2015), incorporating multiple gRNA at once, and filtering out the cell’s own
introduced double stranded breaks (DSBs). In order to be computationally identified,
the DNA is digested to produce sequence reads with the same 5’ ends at cleavage
sites (Kim et al., 2015). One identified setback of this method is that it is indeed
being conducted in vitro rather than in vivo which could possibly lead to skewed
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results (B. X. H. Fu, St. Onge, Fire, & Smith, 2016; Zischewski et al., 2017), but
there is no evidence suggesting that off target effects for a particular guide RNA
would differ between in vitro and in vivo systems.
Ways to minimize
Unlike Zinc Finger Nucleases (ZFN) and transcription activator-like effector
nucleases (TALENs) which are dimeric, CRISPR-Cas9 is monomeric which leads to
a higher likelihood of off-target mutations because it scans for shorter target
sequences. In addition, the sgRNA used can lead to off-target mutations, as certain
sgRNAs can tolerate different amounts of mismatches (Zischewski et al., 2017).
Because sgRNA sequence and length dictates potential off-target sites, it is an
optimal component to modify in order to reduce off-target mutations (Frock et al.,
2015). For example, one could potentially minimize off-target effects by reducing the
gRNA length from 20 nt to 17 or 18 nt to reduce the RNA-DNA binding energy (Y. Fu
et al., 2013). Finally, the nuclease can be engineered to make a double-stranded
break via 2 separate single-stranded cuts by targeting two nearby sequences with a
Cas9 cleavage mutant (a D10A mutant nickase version of Cas9n) (Ran et al., 2013).

Methods and Experimental Design
Goal of study.
The goal of the study is to quantify differences in CRISPR genetic editing
efficiency, in regards to on-target mutations, off-target mutations, and overall
efficiency between in vitro and in vivo editing of mouse eggs.
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Mouse model.
In order to examine the efficiency of CRISPR genetic editing of eggs, the
utilization of a fluorescent mouse model allows for simple detection of efficiency by
physical examination of cultured cells. The mice used in this experiment will have
been bred to express green fluorescent protein (GFP) throughout their bodies
through methods established by Ikawa et al. For the in vitro treatment, pre-existing
mouse cell lines expressing GFP will be used (Ikawa et al., 1995). These GFP
expressing mice will then be mutated into BFP expressing mice via CRISPR-Cas9
using HDR. Successful mutation will result in a blue fluorescence, while NHEJ will
result in a loss of fluorescence due to the creation of small indels.

Guide RNA.
As indicated by Liang et al. (2017), the guide RNA (sgRNA) to target the GFP
gene will be designed and synthesized using GeneArt™ CRISPR gRNA Design Tool
and Synthesis Kit. Qubit® RNA BR Assay Kit will be utilized to compute the
concentration of sgRNA needed.

Donor DNA.
In order to easily identify the efficiency of gene editing in this model, a blue
fluorescent protein (BFP) gene will be used as the donor DNA. Taking into
consideration previous research on the higher rates of HDR when using ssDNA in
comparison to dsDNA as donor DNA (Richardson et al., 2016), this designed BFP
donor DNA will be single stranded. A correct targeting of the GFP sequence and
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integration of the BFP donor DNA will result in the mouse egg cells emitting blue
light when excited.

CRISPR-Cas9 treatment.
In order to standardize the variables between the two treatments, the same
CRISPR treatment system will be used for both. We will use the AAV serotype 8
(AAV8) as a vector for the CRISPR- Staphylococcus aureus Cas9 (SaCas9)
complex with the GFP sgRNA and an oocyte specific promoter, Gdf9 (Salvador,
Silva, Kostetskii, Radice, & Strauss, 2008) (Figure 1). The AAV serotype is an
Adeno-associated virus that infects humans. This delivery system has been shown
effective for the delivery of CRISPR-cas9 systems into mouse skeletal and cardiac
muscle, with this particular smaller Cas9 variant (Nelson et al., 2016). The AAV
vector complex will be either directly microinjected into the oocyte region of the
mouse for the in vivo treatment or transduced to the collection of harvested egg cells
for the in vitro treatment. For the in vivo treatment, identification and surgical
exposure of the female mouse reproductive tract protocol will be used from a study
exploring mouse ovarian fat pads (Flesken-Nikitin, Harlan, & Nikitin, 2016).

Figure 1. AAV8 vector and donor BFP ssDNA with induced mutation.
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Off-target effects measurements.
A targeted sequencing approach can be utilized to measure off-target
mutations in both in vivo and in vitro treatments. This approach will apply digenome
sequencing to identify potential off-target sites that resemble the GFP sequence.
Then, through targeted sequence amplification of the oocyte DNA, these targeted
sites will be sequenced to determine if they were modified by the nuclease enzyme
treatment. The oocytes used for amplification and analysis will either be from the in
vitro CRISPR-Cas9 treatment or harvested from the in vivo treatment. The rates at
which these potential off-target sites are modified in both in vivo and in vitro
treatments can then be determined and compared (Figure 2).
On-target mutation measurements.
To determine efficiency of the two treatment methods in regards to on target
mutations, FACS will be used to determine the rate of on-target mutations. For the in
vitro treatment, the edited unfertilized oocytes will be analyzed through FACS for
fluorescence expression. The in vivo edited oocytes will be harvested after CRISPR
treatment and similarly analyzed via FACS for fluorescence under the appropriate
wavelengths (Figure 2).
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Expected Results and Analysis
Off-target mutations.
Off-target mutation rates allow for a quantification of the likelihood of the
CRISPR complexes to create an unintended mutation at a sequence other than the
target. These rates will be obtained through targeted sequence amplification of the
regions identified by digenome sequencing. A two-tailed t-test will be used to
statistically compare the means of off-target mutation rates from the in vivo and in
vitro treatments. We do not expect to observe a significant difference in the ratio of
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off-target/on-target mutations between the two treatments, as the same gRNA,
donor DNA, and vectors are used. However, we may observe a reduction in the
number of observed off-target mutation in the in vivo treatment, if there is an overall
reduction of efficiency.

On-target mutations.
A quantification of how often the CRISPR complex is both cutting the correct
sequence and effectively incorporating the donor DNA is vital to future claims
regarding the efficiency of CRISPR and its potential clinical use. The in vivo and in
vitro on-target rates will be compared via a two-tailed t-test and analyzed to
determine statistically significant difference. For example, we will compare the
fraction of BFP-expressing cells, GFP-expressing cells, cells lacking fluorescence
between the two treatments. The on-target rates will be characterized by the
appearance of BFP. Although the essential requirements for CRISPR to perform
efficiently within a cell are met in both the in vivo and in vitro treatments and in
theory the on-target mutation rates would not vary significantly between the two, in
vivo delivery may pose a problem. If the CRISPR delivery or exposure is
compromised via the nature of in vivo delivery, we could expect to see a lower ontarget rate and off-target rate amongst the in vivo treatment. However, this result
would not negate further in vivo genetic editing research, but could instead point to a
need for further research of effective in vivo CRISPR complex delivery.
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Overall efficiency.
While off-target rates are characterized as off-target per on-target mutation,
the overall efficiency reflects the overall amount of mutations, any change at all. In
regards to our fluorescence test, this would resemble any change from green to
either blue or non-fluorescence. Although the off-target and on-target may not vary
between the two treatments, the total efficiency should be analyzed. This information
can then be useful when determining the current clinical viability of in vivo genetic
editing of oocytes. If the efficiency is lower but the off-target rate is the same or
lower, this may be interpreted as a low-risk situation.
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CONCLUSION
In the first chapter of this thesis I examined current conservative Christian
discourse on genetic editing and located four major Christian concerns commonly
used in the Christian rejection of genetic editing research and clinical usage. These
concerns (beginning of life, Creator-human relationship, imago Dei, and
stewardship) are also tension zones within the discourse that contain contradictions
and allow for the possibility of potential acceptance of genetic editing. In the second
chapter, I applied this knowledge of tension zones to argue that two areas in which
there is considerable possibility of Christian acceptance of genetic editing are the
stewardship concern of harm and the conjugal act requirement in the creation of new
life. I propose that epigenetics, somatic gene therapy and in vivo genetic editing are
promising research fields that could help produce genetic editing methods that
accommodate previously identified Christian concerns. The final chapter is an
experimental proposal for an analysis of in vivo and in vitro CRISPR-Cas9 genetic
editing efficiency; here efficiency is quantified by both on- and off-target mutation
rates which quantify the amount of correct mutations at the targeted location and the
amount of mutations at different similar-looking sites. This study is important when
determining the clinical possibility of in vivo genetic editing and whether the risks out
way the benefits.
This thesis is important as it shows that not only is it possible to study a
specific discourse to determine important community concerns, but also that it is
possible to scientifically pursue techniques that accommodate these concerns and
allow for wider acceptance. Further studies in the three research fields I proposed
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would support a greater goal of increasing the clinical accessibility of genetic editing.
This is especially important for those who find themselves in situations where they
would like to have the choice of genetic editing but are currently uncomfortable with
contemporary methods. Not only is scientific research important in motivating this
goal, but also religious studies research is important. Further analysis of other, nonmajority religious discourse regarding genetic editing will help us understand their
concerns and develop research paths that can help accommodate those concerns,
producing clinical genetic editing methods that they would feel more comfortable
using.
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